Presentation is loading. Please wait.

Presentation is loading. Please wait.

Randomized Comparison of Four-Times-Daily versus Once-Daily Intravenous Busulfan in Conditioning Therapy for Hematopoietic Cell Transplantation  Seong-Gil.

Published byOnni Aho Modified over 5 years ago

Similar presentations

Presentation on theme: "Randomized Comparison of Four-Times-Daily versus Once-Daily Intravenous Busulfan in Conditioning Therapy for Hematopoietic Cell Transplantation  Seong-Gil."— Presentation transcript:

1 Randomized Comparison of Four-Times-Daily versus Once-Daily Intravenous Busulfan in Conditioning Therapy for Hematopoietic Cell Transplantation  Seong-Gil Ryu, Je-Hwan Lee, Seong-Jun Choi, Jung-Hee Lee, Young-Shin Lee, Miee Seol, Eun-Hye Hur, Soo Han Lee, Kyun Seop Bae, Gyu Jeong Noh, Moo-Song Lee, Sung-Cheol Yun, Sang Beom Han, Kyoo-Hyung Lee  Biology of Blood and Marrow Transplantation  Volume 13, Issue 9, Pages (September 2007) DOI: /j.bbmt Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

2 Figure 1 Busulfan concentration curves of the BU4 and BU1 groups.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

3 Figure 2 Overall survival of the BU4 and BU1 arms.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

4 Figure 3 Nonrelapse mortality of patients in the BU4 and Bu1 treatment groups. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

Download ppt "Randomized Comparison of Four-Times-Daily versus Once-Daily Intravenous Busulfan in Conditioning Therapy for Hematopoietic Cell Transplantation  Seong-Gil."

Similar presentations

Highly Variable Pharmacokinetics of Once-Daily Intravenous Busulfan When Combined with Fludarabine in Pediatric Patients: Phase I Clinical Study for Determination.

Highly Variable Pharmacokinetics of Once-Daily Intravenous Busulfan When Combined with Fludarabine in Pediatric Patients: Phase I Clinical Study for Determination.
Serial Measurement of WT1 Expression and Decrement Ratio Until Hematopoietic Cell Transplantation as a Marker of Residual Disease in Patients with Cytogenetically.

Serial Measurement of WT1 Expression and Decrement Ratio Until Hematopoietic Cell Transplantation as a Marker of Residual Disease in Patients with Cytogenetically.
Influence of GST Gene Polymorphisms on the Clearance of Intravenous Busulfan in Adult Patients Undergoing Hematopoietic Cell Transplantation  Sung-Doo.

Influence of GST Gene Polymorphisms on the Clearance of Intravenous Busulfan in Adult Patients Undergoing Hematopoietic Cell Transplantation  Sung-Doo.
Changes in Serologic Markers of Hepatitis B Following Autologous Hematopoietic Stem Cell Transplantation  Ji Eun Uhm, Kihyun Kim, Tae Kyu Lim, Byeong-Bae.

Changes in Serologic Markers of Hepatitis B Following Autologous Hematopoietic Stem Cell Transplantation  Ji Eun Uhm, Kihyun Kim, Tae Kyu Lim, Byeong-Bae.
Improved Outcome of a Reduced Toxicity-Fludarabine, Cyclophosphamide, plus Antithymocyte Globulin Conditioning Regimen for Unrelated Donor Transplantation.

Improved Outcome of a Reduced Toxicity-Fludarabine, Cyclophosphamide, plus Antithymocyte Globulin Conditioning Regimen for Unrelated Donor Transplantation.
DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic.

DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic.
How to Treat MDS without Stem Cell Transplantation

How to Treat MDS without Stem Cell Transplantation
The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,
Hematopoietic Cell Transplantation Provides Durable Disease Control in Patients with Double-Hit Lymphoma  Taewoong Choi, Murali K. Kodali, Wen-Kai Weng 

Hematopoietic Cell Transplantation Provides Durable Disease Control in Patients with Double-Hit Lymphoma  Taewoong Choi, Murali K. Kodali, Wen-Kai Weng 
Donor-Derived Natural Killer Cells Infused after Human Leukocyte Antigen– Haploidentical Hematopoietic Cell Transplantation: A Dose-Escalation Study  Inpyo.

Donor-Derived Natural Killer Cells Infused after Human Leukocyte Antigen– Haploidentical Hematopoietic Cell Transplantation: A Dose-Escalation Study  Inpyo.
Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes 

Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes 
Pre-Engraftment Syndrome after Unrelated Cord Blood Transplantation: A Predictor of Engraftment and Acute Graft-versus-Host Disease  Meerim Park, Soo.

Pre-Engraftment Syndrome after Unrelated Cord Blood Transplantation: A Predictor of Engraftment and Acute Graft-versus-Host Disease  Meerim Park, Soo.
Allogeneic Stem Cell Transplantation in Myelofibrosis

Allogeneic Stem Cell Transplantation in Myelofibrosis
The Prognostic Value of YKL-40 Concentrations in Nonmyeloablative Conditioning Allogeneic Hematopoietic Cell Transplantation  Anne Mette Mørup, Brian.

The Prognostic Value of YKL-40 Concentrations in Nonmyeloablative Conditioning Allogeneic Hematopoietic Cell Transplantation  Anne Mette Mørup, Brian.
Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched.

Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched.
Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience 

Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience 
Allogeneic Hematopoietic Stem Cell Transplant for Adults over 40 Years Old with Acquired Aplastic Anemia  Hawk Kim, Kyoo-Hyung Lee, Sung-Soo Yoon, Sang.

Allogeneic Hematopoietic Stem Cell Transplant for Adults over 40 Years Old with Acquired Aplastic Anemia  Hawk Kim, Kyoo-Hyung Lee, Sung-Soo Yoon, Sang.
Comparison of Allogeneic Stem Cell Transplantation from Familial- Mismatched/Haploidentical Donors and from Unrelated Donors in Adults with High-Risk.

Comparison of Allogeneic Stem Cell Transplantation from Familial- Mismatched/Haploidentical Donors and from Unrelated Donors in Adults with High-Risk.
Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,
Feasible Outcomes of T Cell–Replete Haploidentical Stem Cell Transplantation with Reduced-Intensity Conditioning in Patients with Myelodysplastic Syndrome 

Feasible Outcomes of T Cell–Replete Haploidentical Stem Cell Transplantation with Reduced-Intensity Conditioning in Patients with Myelodysplastic Syndrome 

Similar presentations

Ads by Google